Literature DB >> 16760320

Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts.

Staffan Görander1, Judica Mbwana, Eligius Lyamuya, Teresa Lagergård, Jan-Ake Liljeqvist.   

Abstract

Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted infection in sub-Saharan Africa. Glycoprotein G (gG) of HSV-2 elicits a type-specific antibody response and is widely used for serodiagnosis. gG is cleaved into a secreted portion (sgG-2) and a highly O-glycosylated mature portion (mgG-2). The performances of these two native immunosorbent purified antigens were compared in an enzyme-linked immunosorbent assay (ELISA) format with a commercially available assay (FOCUS2) using sera from blood donors (n = 194) and individuals (n = 198) with genital ulcer disease (GUD) from Tanzania. Discordant results were resolved by Western blotting. The HSV-2 seroprevalence for blood donors was estimated as 42%, and that for the GUD cohort was estimated as 78%. The prevalence increased significantly with age for both cohorts and was higher among human immunodeficiency virus (HIV)-positive individuals than among HIV-negative subjects. In the GUD cohort with a high HSV-2 prevalence, all three assays showed statistically similar performances, with sensitivities between 97% and 99% and specificities in the range of 86% to 91%. In contrast, among blood donors with a lower seroprevalence, the mgG-2-based ELISA presented significantly higher specificity (97%) than the sgG-2 ELISA (89%) and FOCUS2 (74%). Overall, the mgG-2 ELISA gave a high performance, with negative and positive predictive values of 96% for blood donors and a negative predictive value of 95% and a positive predictive value of 97% for the GUD cohort. We conclude that native purified mgG-2 showed the highest accuracy for detection of HSV-2 in patient sera from Tanzania and is therefore suitable for seroprevalence studies as well as in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760320      PMCID: PMC1489561          DOI: 10.1128/CVI.00051-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  35 in total

1.  Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection.

Authors:  C Y Chen; R C Ballard; C M Beck-Sague; Y Dangor; F Radebe; S Schmid; J B Weiss; V Tshabalala; G Fehler; Y Htun; S A Morse
Journal:  Sex Transm Dis       Date:  2000-01       Impact factor: 2.830

2.  Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants.

Authors:  Jan-Åke Liljeqvist; Edward Trybala; Johan Hoebeke; Bo Svennerholm; Tomas Bergström
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

3.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.

Authors:  Anna Wald; Katherine Link
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

4.  Glycoprotein G of herpes simplex virus type 1: identification of type-specific epitopes by human antibodies.

Authors:  P Tunbäck; J A Liljeqvist; G B Löwhagen; T Bergström
Journal:  J Gen Virol       Date:  2000-04       Impact factor: 3.891

5.  Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania.

Authors:  Andwele Mwansasu; Davis Mwakagile; Lars Haarr; Nina Langeland
Journal:  J Clin Virol       Date:  2002-04       Impact factor: 3.168

6.  Herpes simplex virus type-selective enzyme-linked immunosorbent assay with Helix pomatia lectin-purified antigens.

Authors:  B Svennerholm; S Olofsson; S Jeansson; A Vahlne; E Lycke
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

Review 7.  Performance and use of HSV type-specific serology test kits.

Authors:  Rhoda L Ashley
Journal:  Herpes       Date:  2002-07

Review 8.  Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review.

Authors:  Jennifer S Smith; N Jamie Robinson
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

9.  Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, Western blotting, and gG2 inhibition.

Authors:  Wayne Hogrefe; Xin Su; James Song; Rhoda Ashley; Lilly Kong
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities.

Authors:  Hinda J Ahmed; Judica Mbwana; Eva Gunnarsson; Karin Ahlman; Chalamilla Guerino; Liselott A Svensson; Fred Mhalu; Teresa Lagergard
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

View more
  7 in total

1.  Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda.

Authors:  Jordyn L Gamiel; Aaron A R Tobian; Oliver B Laeyendecker; Steven J Reynolds; Rhoda Ashley Morrow; David Serwadda; Ronald H Gray; Thomas C Quinn
Journal:  Clin Vaccine Immunol       Date:  2008-03-05

2.  Herpes simplex virus type-2 assay specificity and male circumcision to reduce herpes simplex virus type-2 acquisition.

Authors:  Aaron A R Tobian; Godfrey Kigozi; Maria J Wawer; David Serwadda; Thomas C Quinn; Ronald H Gray
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

3.  Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2.

Authors:  Jérôme LeGoff; Philippe Mayaud; Gérard Gresenguet; Helen A Weiss; Khonde Nzambi; Eric Frost; Jacques Pepin; Laurent Belec
Journal:  J Clin Microbiol       Date:  2008-04-02       Impact factor: 5.948

4.  Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Authors:  Staffan Görander; Teresa Lagergård; Malgorzata Romanik; Raphael P Viscidi; Gayane Martirosian; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

Review 5.  Exploitation of glycosylation in enveloped virus pathobiology.

Authors:  Yasunori Watanabe; Thomas A Bowden; Ian A Wilson; Max Crispin
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-05-20       Impact factor: 3.770

Review 6.  Glycan Nanostructures of Human Coronaviruses.

Authors:  Wanru Guo; Harini Lakshminarayanan; Alex Rodriguez-Palacios; Robert A Salata; Kaijin Xu; Mohamed S Draz
Journal:  Int J Nanomedicine       Date:  2021-07-15

7.  Prevalence of viral sexually transmitted infections and HPV high-risk genotypes in women in rural communities in the Department of La Paz, Bolivia.

Authors:  Marianela Patzi-Churqui; Katty Terrazas-Aranda; Jan-Åke Liljeqvist; Magnus Lindh; Kristina Eriksson
Journal:  BMC Infect Dis       Date:  2020-03-06       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.